Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.55 |
| ▸ | CTSS | P25774 | 13/20 | 0.55 |
| ▸ | CTSL | P07711 | 11/20 | 0.55 |
| ▸ | CTSB | P07858 | 8/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716195 | 0.79 | CTSK (0.51) | CTSKCTSSCTSLCTSB | |
| SCHEMBL14291024 | 0.76 | CTSK (0.77) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4715050 | 0.72 | CTSK (1.00) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4129755 | 0.70 | CTSL (0.47) | CTSKCTSSCTSL | |
| SCHEMBL4712693 | 0.70 | CTSK (0.73) | CTSKCTSSCTSLCTSB | |
| SCHEMBL9253347 | 0.70 | PRMT6 (0.43) | — | |
| SCHEMBL4711862 | 0.70 | CTSK (0.98) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4714654 | 0.69 | CTSK (1.00) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4716587 | 0.68 | CTSK (0.82) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4712315 | 0.68 | CTSK (0.82) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1248612-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-6525036-B2 | Treating post-menopausal osteoporosis. | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1248612-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-16 | — | — | EP | disclosed |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | Celera Corporation | 2002-05-02 | — | — | US | disclosed |
| WO-2001049288-A9 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001049288-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, CTRL, SPINT2 | CTSK 52/4885CTSS 27/4885CTSL 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.